Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0526800B2 - - Google Patents
[go: Go Back, main page]

JPH0526800B2 - - Google Patents

Info

Publication number
JPH0526800B2
JPH0526800B2 JP58053922A JP5392283A JPH0526800B2 JP H0526800 B2 JPH0526800 B2 JP H0526800B2 JP 58053922 A JP58053922 A JP 58053922A JP 5392283 A JP5392283 A JP 5392283A JP H0526800 B2 JPH0526800 B2 JP H0526800B2
Authority
JP
Japan
Prior art keywords
rheumatoid
patients
plasma
mobility
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58053922A
Other languages
Japanese (ja)
Other versions
JPS59180363A (en
Inventor
Naoki Yamanaka
Osamu Oda
Toshihisa Kanamono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Medical Co Ltd
Original Assignee
Asahi Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Medical Co Ltd filed Critical Asahi Medical Co Ltd
Priority to JP58053922A priority Critical patent/JPS59180363A/en
Publication of JPS59180363A publication Critical patent/JPS59180363A/en
Publication of JPH0526800B2 publication Critical patent/JPH0526800B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は、慢性関節リウマチ等のリウマチ血漿
中から単離したリウマチ特異蛋白質(以下RPと
称す)に関するものである。 現在リウマチの診断は、医師の所見や患者主訴
に負うところが多く、客観的、定量的診断法が望
まれているのが実状である。この診断法としては
一般に、11項目から成るアメリカリウマチ協会の
診断基準が採用されており、それらのうち、何項
目を満たすかによつてリウマチの診断が行なわれ
ている。その基準項目の一つにリウマチ因子の検
出があり、測定法が簡便であるためリウマチ因子
の検出は日常検査として広く行なわれている。 ところで、リウマチ因子はリウマチ患者血漿中
に高率に認められるが(報告によつて異なるがリ
ウマチ患者の40〜70%でリウマチ因子が検出され
ている)、肝疾患患者、癌患者などのリウマチ以
外の患者血漿中においても高頻度に認められ(肝
硬変患者では50%以上、癌患者の20%近くでリウ
マチ因子陽性との報告がある)、また、健常人の
3〜7%にも認められている。このように、リウ
マチにおけるリウマチ因子存在の特異性は低く、
リウマチ因子の存在より直ちにリウマチとの診断
を行なうことはできない。先のアメリカリウマチ
協会の診断基準においてもリウマチ因子の存在
は、リウマチの診断において、必要なあるいは十
分な条件とは認められていない。つまり、リウマ
チの確定診断において、リウマチ因子を測定する
ことは実際上の有用性は低く、したがつて、リウ
マチ因子に代わるリウマチ診断のためのパラメー
ターが嘱望されている。 本発明者らは、多数のリウマチ患者および他の
疾患患者、健常人の血漿について研究した結果、
リウマチ患者血漿中に、他の疾患患者や健常人の
血漿中には認められない新規蛋白質(RP)が高
率に発現されていることを、蛋白変性剤を用いな
い2次元電気泳動法(以下の2次元電気泳動はす
べて蛋白変性剤を用いていない)により発見し、
これを単離することに成功した。本発明者らの研
究結果によれば、RPはリウマチ患者の70〜80%
において認められ、しかも、健常人や腎不全患
者、肝疾患患者、癌患者では全く認められなかつ
た。従来知られているリウマチ因子がリウマチ患
者の40〜70%で陽性であり、かつ健常人や肝疾患
患者、癌患者らにおいても高率に見られることに
比べて、RPの特異性およびリウマチ患者におけ
る陽性率は共に明らかに高い。したがつて、RP
に対して特異的な抗体(RP−Ab)を作成して、
RP−Abを用いた診断薬によつて、日常の臨床検
査としてRPの検出を行なうことは、リウマチの
診断の有力な手段となりうる。このRP−Abの作
成に取得されたRPは必要であり、よつてリウマ
チ診断においてRPおよびRP−Abは共に極めて
有用である。 RPは、リウマチ血漿を2次元電気泳動する時、
等電点(pI)7.3〜7.8、移動度(アルブミン最先
端部の移動度を1.0として)0.40〜0.55の範囲にス
ポツトとして認められる、SDSポリアクリルアミ
ドゲル電気泳動による分子量が約170000の蛋白質
であり、そのアミノ酸組成は下記のとおりである
(単位はmole%)。 Lys 6.6, His 1.9, Arg 4.0, Asp 7.0,
Thr 8.5, Ser10.0, Glu 10.4, Pro 7.9,
Gly10.4, Ala 4.7, Cys/2 1.0,Val 7.5,
Met 1.6, Ile 2.9, Leu 8.3, Tyr 4.5,
Phe 2.9 健常人血漿の2次元電気泳動においては、等電
点(pI)が7.3〜7.8、移動度(アルブミン最先端
部の移動度を1.0として)が0.40〜0.55の範囲には
蛋白質は認められず、RPはリウマチ血漿中にみ
られる、従来知られていない全く新しい蛋白質で
あることがわかる。 次に、RPの取得方法について述べる。RPは、
一般的手法により得たリウマチ血漿を、まずポリ
アクリルアミドゲルにより等電点電気泳動し、続
いて濃度勾配ゲル電気泳動する2次元電気泳動法
によつて2次元電気泳動ゲル上に分離することが
できる。RPは2次元電気泳動ゲル上の等電点
(pI)7.3〜7.8、移動度(アルブミン最先端部の移
動度を1.0として)0.40〜0.55の範囲にあり、これ
を2次元電気泳動ゲル上より分割して緩衝液等に
より抽出し、単離できる。このとき単離したRP
の分子量は、SDSポリアクリルアミドゲル電気泳
動法によつて測定する時、約170000である。 また、大量にRPを単離するには、リウマチ患
者血漿の25〜35%飽和硫酸アンモニウムで塩析さ
れる沈澱について、DEAE−セフアデツクスA−
50(フアルマシア社製、スウエーデン)等のよう
なイオン交換ゲルによるイオン交換クロマトグラ
フイーを行ない、0.5M塩化ナトリウムで溶出さ
れる分画を回収する。さらに、この分画をセフア
クリルS−300(フアルマシア社製、スウエーデ
ン)等のようなゲルによるゲルクロマトグラフイ
ーの後、再度上記のイオン交換ゲルによるイオン
交換クロマトグラフイーを行なうことにより単離
できる。このとき単離したRPは、2次元電気泳
動する時、等電点(pI)7.3〜7.8、移動度(アル
ブミン最先端部の移動度を1.0として)0.40〜0.55
の範囲にあり、SDSポリアクリルアミドゲル電気
泳動法によつて測定する時、約170000の分子量を
示す。 RPに特異な抗体RP−Abは、例えば精製した
RPをフロインド(Freund)の完全アジユバント
等と共に免疫可能な動物に免疫して、その免疫動
物から抗血清を採取して精製する、特異抗体作成
の一般的方法によつて得られる。抗血清からの抗
体の精製は、例えば抗原であるRPを臭化シアン
等のリガンドによつてセフアロース4B(フアルマ
シア社製、スウエーデン)等のゲルに結合させ、
そのゲルをつめたカラムに抗血清を通し、よく洗
浄の後、グリシン緩衝液等によりカラムから抗体
を分離する免疫吸着法等によつてできる。このよ
うにして得た抗体RP−Abは、一般的な特異抗体
の確認法、例えば免疫電気泳動や免疫沈降反応等
によつて、精製したRPと特異的に反応して沈降
線を生ずることより確認できる。 RP−Abによる血漿中のRPの測定は、現在一
般に行なわれている特異抗体を用いた抗原測定の
方法、例えば、寒天等のゲルを用いた二重免疫拡
散法や、ラテツクスや赤血球等にRP−Abを固定
して行なう各種凝集反応、ビーズやマイクロプレ
ート等の固相にRP−Abを吸着させて酵素やラジ
オアイソトープ等を用いる免疫測定法等によりで
きる。このような測定方法等によつてRP−Abを
用いてRPが簡便に測定でき、したがつて、リウ
マチ診断のための日常検査法としてRP−Abは重
要である。 実施例 <RPの単離方法> RPを有する慢性関節リウマチ患者における血
漿交換によつて生じた排血漿の、25%飽和硫酸ア
ンモニウムによつて析出した沈澱を、8000×g,
20分の遠心分離によつて除き、上清に更に硫酸ア
ンモニウムを加えて、35%飽和硫酸アンモニウム
により析出した沈澱を8000×g,20分の遠心分離
により回収した。この沈澱を0.02Mリン酸緩衝液
(PH7.2、以下PBNaと称す)で溶解し、セロフア
ン膜により脱イオン水で透析して硫酸アンモニウ
ムを除去し、次に、あらかじめPBNaで緩衝化し
たDEAE−セフアデツクスA−50(フアルマシア
社製、スウエーデン)カラムを用いてイオン交換
クロマトグラフイーを行なつた。0.5M塩化ナト
リウム液によつて溶出される分画にRPが含まれ
ていることを2次元電気泳動法によつて確認し、
この分画を回収した。回収した分画は、セロフア
ン膜により脱イオン水で2回透析して塩化ナトリ
ウムを除去した後、凍結乾燥によつて濃縮し、さ
らにセフアクリルS−300(フアルマシア社製、ス
ウエーデン)カラムによりゲルクロマトグラフイ
ーを行ない、2次元電気泳動法によつてRPが確
認された分画位置に相当する分画を回収すること
により、イオン交換クロマトグラフイーで混入し
たRPと分子ふるいの挙動が異なる物質を分離し
た。この後、再度DEAE−セフアデツクスA−50
(フアルマシア社製、スウエーデン)カラムを用
いてイオン交換クロマトグラフイーによるイオン
強度による分離をさらに行ない、塩化ナトリウム
の0.0Mから0.6Mの濃度勾配液で溶出させて、2
次元電気泳動法によりRPが確認された分画位置
に相当する分画を回収して、精製したRPを得た。 この精製したRPを検体として以下のように2
次元電気泳動を行ない、確認した。精製した
RP60μl(蛋白濃度0.40mg/ml)を、アンフオライ
ン〔Ampholine:フアルマシア社製、6.25w/v
%(PH3.5−10:PH3.5−5=4:1)〕を含むポ
リアクリルアミドゲル上で、0.01Mリン酸液と
0.04N水酸化ナトリウム液を用いて、はじめ一定
電流(2mA)で泳動し、電圧が220Vに達した
後、220Vの一定電圧で20時間泳動した。次に、
この泳動ゲルを4%から17%の濃度勾配をもつポ
リアクリルアミド・スラブゲル上に置いて、一定
電流(24mA)で20時間泳動した。この時の泳動
液には、0.05Mトリスー0.384Mグリシン緩衝液
を用いた。以上のようにして2次元電気泳動した
後、0.025%コマシー・ブリリアント・ブルー
(Coomersie Brilliant Blue R−250),50v/v
%メタノール、7%酢酸液で8時間染色し、7%
酢酸、10%メタノール液で3日間脱色して得た泳
動像を第1図に示す。泳動像は等電点7.3〜7.8、
移動度(アルブミン最先端部の移動度を1.0とし
て)0.40〜0.55の範囲内にあることよりRPである
ことを確認した。また、この時得たRPは、SDS
ポリアクリルアミドゲル電気泳動によつて、分子
量約170000と測定できた。 参考までに、慢性関節リウマチ患者血漿および
健常人血漿を同様に2次元電気泳動を行なつた場
合の泳動像を、それぞれ第2図および第3図に示
す。慢性関節リウマチ患者血漿の2次元電気泳動
像には、等電点7.3〜7.8、移動度(アルブミン最
先端部の移動度を1.0として)0.40〜0.55の範囲内
にRPのスポツトがみられる(破線で囲んだ部
分)。しかしながら、健常人血漿の2次元電気泳
動像には、等電点7.3〜7.8、移動度(アルブミン
最先端部の移動度を1.0として)0.40〜0.55の範囲
内には、RPはもとより蛋白質のスポツトは全く
認められない。 精製したRPは、UVスペクトル280nmに極大
吸収を持ち、ニンヒドリン陽性であり、また、
RAテスト、RAHA,Immune Complexテスト
を行ない、RPが従来知られているリウマチ因子
やImmune Complexでないことも同時に確認し
た。 さらに、精製したRPを6N塩酸で110℃で24時
間加水分解後、アミノ酸分析機(日立KLH−5)
によつてアミノ酸の分析を行なつた。この時得た
結果は、次のようであつた(単位はmole%)。 Lys 6.6,His 1.9,Arg 4.0,Asp 7.0,Thr
8.5,Ser 10.0,Glu 10.4,Pro 7.9,Gly 10.4,
Ala 4.7,Cys/2 1.0,Val 7.5,Met 1.6,Ile
2.9,Leu 8.3,Tyr 4.5,Phe 2.9 <RP−Abの作成> 免疫動物として家兎を用いて、精製したRP1ml
(蛋白量0.32mg)とフロインド(Freund)完全ア
ジユバント1mlを混ぜ合せて、安定な油中水型エ
マルジヨンを作成し、成熟家兎皮下に注射した。
1ケ月後に、精製したRP1ml(蛋白量0.40mg)と
フロインド(Freund)完全アジユバント1mlを
混ぜ合せて、安定な油中水型エマルジヨンを再度
作成し、同じ家兎に皮下注射した。さらに1週間
後に採血して抗血清を得た。 抗血清からの抗体の精製は次のようにして行な
つた。まずセフアロース4B(フアルマシア社製、
スウエーデン)20mlをブツフナー(Buchner)漏
斗上で蒸留水であらかじめ洗浄しておき、それに
蒸留水20mlと臭化シアン水溶液(2g/40ml)を
加えて、4N水酸化ナトリウムで直ちにPHを11.0
とした。これをPHを11.0〜11.3に保つたまま8分
間攪拌し、8分後にゲルをブツフナー漏斗で吸引
濾過し、漏斗上のゲルを氷冷しておいた0.1mol
炭酸ナトリウム緩衝液(PH9.0)で3回洗浄し、
吸引濾過して水をきつて氷水浴中に置いた。別
に、精製したRP20mlを炭酸ナトリウム緩衝液で
セロフアン膜を用いて透析し、氷冷しておいたも
のを、作成しておいた氷水浴中のゲルに加えて10
分間攪拌して抗原結合ゲルを作成した。この抗原
結合ゲルをカラムにつめ、PBNaで洗浄した後、
家兎から得た抗血清10mlを流して抗血清中のRP
−Abを抗原結合ゲルに吸着させた。PBNaで十
分に洗浄した後、RP−AbはPH2.3のグリシン緩
衝液(0.17M)をカラムに流して回収し、直ちに
1/10量のPH11.5のグリシン緩衝液(1M)を加え
て中和し、RP−Abを精製・単離した。精製した
RP−Abは、次のようにして確認した。まず精製
したRPを2次元電気泳動で展開した後、あらか
じめ1%寒天に0.5mlの精製したRP−Abを混合
した液を、2次元電気泳動によつて展開しておい
たゲル上に流し、寒天が固化後、1日室温に放置
して免疫沈降反応を行なつた。 免疫沈降反応後寒天に生じた沈降スポツトは、
等電点7.3〜7.8、移動度(アルブミンの最先端部
移動度を1.0として)0.40〜0.55の範囲内にあつ
た。この時得た沈降スポツトを第4図に示す。
RPに特異な抗体RP−Abが精製できたことが示
された。 <RP−Abによるリウマチ診断例> 医師による総合的診断結果により確認された慢
性関節リウマチ患者60例、健常人30例、腎不全患
者20例、肝疾患患者(肝硬変など)12例、癌患者
(胃癌、大腸癌など)40例について、RP−Abを
用いた二重免疫拡散法と、市販のRAテストキツ
ト(日水製薬製)によるリウマチ因子の測定の両
法(以下それぞれRP−Ab法とRAテストと称す
る)によつてリウマチの診断を行なつた。RP−
Ab法における陽性・陰性は沈降線の有無により
判定した。この時、精製したRPを陽性対照、RP
を含まないことを確認ずみの血漿を陰性対照とし
て各テスト毎においた。RAテストは製造元能書
にしたがつて判定した。結果を第1表に示す。
The present invention relates to a rheumatoid-specific protein (hereinafter referred to as RP) isolated from rheumatoid plasma such as rheumatoid arthritis. Diagnosis of rheumatism currently relies largely on the doctor's findings and the patient's chief complaint, and the reality is that an objective, quantitative diagnostic method is desired. This diagnostic method generally employs the American Rheumatism Association's diagnostic criteria consisting of 11 items, and rheumatism is diagnosed based on how many of these items are met. One of the standard items is the detection of rheumatoid factor, and because the measurement method is simple, detection of rheumatoid factor is widely performed as a routine test. By the way, rheumatoid factor is found at a high rate in the plasma of rheumatoid patients (depending on the report, rheumatoid factor has been detected in 40-70% of rheumatoid patients), but rheumatoid factor is detected in patients with non-rheumatoid conditions such as liver disease patients and cancer patients. It is frequently found in the plasma of patients with cirrhosis (more than 50% of patients with liver cirrhosis and nearly 20% of cancer patients are reported to be rheumatoid factor positive), and it is also found in 3-7% of healthy people. There is. Thus, the specificity of the presence of rheumatoid factors in rheumatism is low;
A diagnosis of rheumatism cannot be made immediately based on the presence of rheumatoid factor. Even in the diagnostic criteria of the American Rheumatology Association, the presence of rheumatoid factors is not recognized as a necessary or sufficient condition for the diagnosis of rheumatism. In other words, measuring rheumatoid factors has little practical utility in definitively diagnosing rheumatism, and therefore there is a need for parameters for rheumatoid diagnosis that can replace rheumatoid factors. As a result of research on the plasma of many rheumatism patients, patients with other diseases, and healthy people, the present inventors found that
Two-dimensional electrophoresis (hereinafter referred to as RP), which does not use a protein denaturing agent, was used to confirm that a novel protein (RP), which is not observed in the plasma of patients with other diseases or healthy individuals, is expressed at a high rate in the plasma of rheumatoid arthritis patients. 2-dimensional electrophoresis (all without using protein denaturants),
We succeeded in isolating this. According to our research results, RP affects 70-80% of rheumatism patients.
Moreover, it was not observed at all in healthy subjects, patients with renal failure, patients with liver disease, or patients with cancer. The previously known rheumatoid factor is positive in 40-70% of rheumatoid patients, and is also found at a high rate in healthy people, liver disease patients, and cancer patients. The positive rates for both cases are clearly high. Therefore, RP
Create an antibody (RP-Ab) specific to
Detection of RP as a routine clinical test using a diagnostic agent using RP-Ab can be an effective means for diagnosing rheumatism. The obtained RP is necessary for the production of this RP-Ab, and therefore both RP and RP-Ab are extremely useful in rheumatism diagnosis. When RP performs two-dimensional electrophoresis of rheumatoid plasma,
It is a protein with a molecular weight of approximately 170,000 as determined by SDS polyacrylamide gel electrophoresis, with an isoelectric point (pI) of 7.3 to 7.8 and a mobility (assuming the mobility of the leading edge of albumin to 1.0) as spots in the range of 0.40 to 0.55. , its amino acid composition is as follows (unit: mole%). Lys 6.6, His 1.9, Arg 4.0, Asp 7.0,
Thr 8.5, Ser10.0, Glu 10.4, Pro 7.9,
Gly10.4, Ala 4.7, Cys/2 1.0, Val 7.5,
Met 1.6, Ile 2.9, Leu 8.3, Tyr 4.5,
Phe 2.9 In two-dimensional electrophoresis of healthy human plasma, no proteins are observed in the range of isoelectric point (pI) of 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin to 1.0) of 0.40 to 0.55. First, it turns out that RP is a completely new, previously unknown protein found in rheumatoid plasma. Next, we will discuss how to obtain RP. RP is
Rheumatoid plasma obtained by a general method can be separated on a two-dimensional electrophoresis gel by a two-dimensional electrophoresis method in which rheumatoid plasma is first subjected to isoelectric focusing using a polyacrylamide gel, followed by concentration gradient gel electrophoresis. . RP has an isoelectric point (pI) of 7.3 to 7.8 on a two-dimensional electrophoresis gel and a mobility of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). It can be isolated by dividing and extracting with a buffer or the like. RP isolated at this time
The molecular weight of is approximately 170,000 as determined by SDS polyacrylamide gel electrophoresis. In addition, in order to isolate a large amount of RP, the precipitate salted out with 25-35% saturated ammonium sulfate from rheumatoid patient plasma should be prepared using DEAE
Perform ion exchange chromatography using an ion exchange gel such as 50 (manufactured by Pharmacia, Sweden), and collect the fraction eluted with 0.5 M sodium chloride. Furthermore, this fraction can be isolated by performing gel chromatography using a gel such as Sephacryl S-300 (manufactured by Pharmacia, Sweden) and then performing ion exchange chromatography using the above-mentioned ion exchange gel. When subjected to two-dimensional electrophoresis, the isolated RP has an isoelectric point (pI) of 7.3 to 7.8 and a mobility (assuming the mobility of the leading edge of albumin to 1.0) of 0.40 to 0.55.
It has a molecular weight of about 170,000 when measured by SDS polyacrylamide gel electrophoresis. RP-specific antibody RP-Ab can be purified, e.g.
It can be obtained by a general method for producing specific antibodies, which involves immunizing an immunizable animal with RP together with Freund's complete adjuvant, etc., and collecting and purifying antiserum from the immunized animal. For purification of antibodies from antiserum, for example, the antigen RP is bound to a gel such as Sepharose 4B (manufactured by Pharmacia, Sweden) using a ligand such as cyanogen bromide, and
Antiserum is passed through a column filled with the gel, and after thorough washing, the antibody is separated from the column using a glycine buffer, etc., using an immunoadsorption method or the like. The antibody RP-Ab obtained in this way can be confirmed to specifically react with purified RP to produce a precipitation line using general specific antibody confirmation methods such as immunoelectrophoresis and immunoprecipitation reaction. Can be confirmed. Measurement of RP in plasma using RP-Ab can be performed using currently commonly used antigen measurement methods using specific antibodies, such as the double immunodiffusion method using a gel such as agar, or the method of measuring RP in latex or red blood cells. This can be done by various agglutination reactions performed by immobilizing -Ab, or by immunoassay using enzymes, radioisotopes, etc. by adsorbing RP-Ab onto a solid phase such as beads or microplates. RP can be easily measured using RP-Ab by such a measurement method, and therefore RP-Ab is important as a routine test method for rheumatism diagnosis. Example <Method for isolating RP> A precipitate precipitated with 25% saturated ammonium sulfate from excreted plasma generated by plasma exchange in a rheumatoid arthritis patient with RP was collected at 8000 x g.
The supernatant was removed by centrifugation for 20 minutes, ammonium sulfate was further added to the supernatant, and the precipitate precipitated with 35% saturated ammonium sulfate was collected by centrifugation at 8000 xg for 20 minutes. This precipitate was dissolved in 0.02M phosphate buffer (PH7.2, hereinafter referred to as PBNa) and dialyzed against deionized water through a cellophane membrane to remove ammonium sulfate. Ion exchange chromatography was performed using an A-50 (manufactured by Pharmacia, Sweden) column. It was confirmed by two-dimensional electrophoresis that RP was contained in the fraction eluted with 0.5M sodium chloride solution,
This fraction was collected. The collected fractions were dialyzed twice against deionized water through a cellophane membrane to remove sodium chloride, concentrated by freeze-drying, and then subjected to gel chromatography using a Sephacryl S-300 (Pharmacia, Sweden) column. By collecting fractions corresponding to the fractional positions where RP was confirmed by two-dimensional electrophoresis, we separated substances whose molecular sieve behavior differs from the contaminated RP by ion-exchange chromatography. . After this, DEAE A-50 again
Separation based on ionic strength was further performed by ion exchange chromatography using a column (manufactured by Pharmacia, Sweden), and eluted with a concentration gradient of 0.0M to 0.6M sodium chloride.
Fractions corresponding to the fractional positions where RP was confirmed by dimensional electrophoresis were collected to obtain purified RP. Using this purified RP as a sample, perform the following two steps.
This was confirmed by dimensional electrophoresis. refined
Add 60μl of RP (protein concentration 0.40mg/ml) to Ampholine (manufactured by Pharmacia, 6.25w/v).
% (PH3.5-10:PH3.5-5=4:1)] on a polyacrylamide gel containing 0.01M phosphoric acid solution.
Using 0.04N sodium hydroxide solution, electrophoresis was performed at a constant current (2 mA) at first, and after the voltage reached 220 V, electrophoresis was performed at a constant voltage of 220 V for 20 hours. next,
This running gel was placed on a polyacrylamide slab gel with a concentration gradient of 4% to 17% and run at constant current (24 mA) for 20 hours. A 0.05M Tris-0.384M glycine buffer was used as the electrophoresis solution at this time. After two-dimensional electrophoresis as described above, 0.025% Coomersie Brilliant Blue (Coomersie Brilliant Blue R-250), 50v/v
% methanol, 7% acetic acid solution for 8 hours, 7%
FIG. 1 shows an electrophoretic image obtained by decolorizing with acetic acid and 10% methanol solution for 3 days. The electrophoresis image has an isoelectric point of 7.3 to 7.8,
It was confirmed that it was RP because the mobility was within the range of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). Also, the RP obtained at this time is SDS
The molecular weight was determined to be approximately 170,000 by polyacrylamide gel electrophoresis. For reference, two-dimensional electrophoresis images of plasma from patients with rheumatoid arthritis and plasma from healthy individuals are shown in FIGS. 2 and 3, respectively. In a two-dimensional electrophoresis image of plasma from a rheumatoid arthritis patient, spots of RP are seen within the range of isoelectric point 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin is 1.0) 0.40 to 0.55 (dashed line). ). However, in a two-dimensional electrophoretic image of plasma from a healthy person, there are not only RP but also protein spots within the isoelectric point of 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin to 1.0) of 0.40 to 0.55. is not accepted at all. Purified RP has maximum absorption at 280 nm in the UV spectrum, is ninhydrin positive, and
RA test, RAHA, and Immune Complex test were performed, and it was also confirmed that RP was not the previously known rheumatoid factor or Immune Complex. Furthermore, after hydrolyzing the purified RP with 6N hydrochloric acid at 110℃ for 24 hours,
Amino acid analysis was carried out by . The results obtained at this time were as follows (unit: mole%). Lys 6.6, His 1.9, Arg 4.0, Asp 7.0, Thr
8.5,Ser 10.0,Glu 10.4,Pro 7.9,Gly 10.4,
Ala 4.7, Cys/2 1.0, Val 7.5, Met 1.6, Ile
2.9, Leu 8.3, Tyr 4.5, Phe 2.9 <Creation of RP-Ab> 1 ml of purified RP using a domestic rabbit as the immunized animal
(protein content: 0.32 mg) was mixed with 1 ml of Freund's complete adjuvant to prepare a stable water-in-oil emulsion, which was injected subcutaneously into adult rabbits.
One month later, a stable water-in-oil emulsion was prepared again by mixing 1 ml of purified RP (protein content 0.40 mg) with 1 ml of Freund's complete adjuvant and injected subcutaneously into the same rabbit. After another week, blood was collected to obtain antiserum. Antibody was purified from antiserum as follows. First, Cepharose 4B (manufactured by Pharmacia,
Pre-wash 20 ml (Sweden) with distilled water on a Buchner funnel, add 20 ml of distilled water and aqueous cyanogen bromide solution (2 g/40 ml), and immediately adjust the pH to 11.0 with 4N sodium hydroxide.
And so. This was stirred for 8 minutes while maintaining the pH between 11.0 and 11.3, and after 8 minutes, the gel was suction-filtered using a Bützner funnel, and the gel on the funnel was ice-cooled.
Wash three times with sodium carbonate buffer (PH9.0),
Filter the water with suction and place in an ice water bath. Separately, 20 ml of purified RP was dialyzed against sodium carbonate buffer using a cellophane membrane, cooled on ice, and added to the prepared gel in an ice water bath for 10 minutes.
The antigen-binding gel was prepared by stirring for a minute. After packing this antigen-binding gel into a column and washing it with PBNa,
Pour 10 ml of antiserum obtained from a domestic rabbit to remove RP in the antiserum.
-Ab was adsorbed to antigen-binding gel. After thorough washing with PBNa, RP-Ab was collected by running a PH2.3 glycine buffer (0.17M) through the column, and immediately added 1/10 volume of a PH11.5 glycine buffer (1M). After neutralization, RP-Ab was purified and isolated. refined
RP-Ab was confirmed as follows. First, purified RP was developed by two-dimensional electrophoresis, and then a mixture of 0.5 ml of purified RP-Ab in 1% agar was poured onto the gel that had been developed by two-dimensional electrophoresis. After the agar solidified, it was left at room temperature for one day to perform an immunoprecipitation reaction. The precipitated spots formed on the agar after the immunoprecipitation reaction are
The isoelectric point was within the range of 7.3 to 7.8, and the mobility was within the range of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). The sedimentation spots obtained at this time are shown in Figure 4.
It was shown that the RP-specific antibody RP-Ab could be purified. <Examples of rheumatism diagnosis using RP-Ab> 60 patients with rheumatoid arthritis confirmed by comprehensive diagnosis by a doctor, 30 healthy people, 20 patients with renal failure, 12 patients with liver disease (cirrhosis, etc.), cancer patients ( For 40 cases (gastric cancer, colorectal cancer, etc.), double immunodiffusion method using RP-Ab and rheumatoid factor measurement using a commercially available RA test kit (manufactured by Nissui Pharmaceutical Co., Ltd.) (hereinafter referred to as RP-Ab method and RA Diagnosis of rheumatism was made using a test (referred to as a test). RP−
Positive/negative results in the Ab method were determined by the presence or absence of a sedimentation line. At this time, use purified RP as a positive control, RP
Plasma, which had been confirmed to be free of , was used as a negative control for each test. The RA test was determined according to the manufacturer's instructions. The results are shown in Table 1.

【表】【table】

【表】 慢性関節リウマチ患者におけるRP−Ab法によ
る陽性率が76.7%(偽陰性23.3%)であつたのに
対して、RAテストによる陽性率は60.0%(偽陰
性40.0%)であり、感度はRAテストに比べてRP
−Ab法の方が明らかに高かつた。また、健常人、
腎不全患者、肝疾患患者および癌患者において
は、RP−Ab法では全く偽陽性が認められなかつ
たのに対して、RAテストでは疾患によつて異な
るものの6.7〜33.3%もの偽陽性が認められ、RA
テストに比べてRP−Ab法の方が明らかに特異性
は高かつた。以上の結果より、従来用いられてい
るリウマチ因子の測定による方法に比べて、RP
−Ab法によるリウマチ診断法は明らかに優れて
おり、RP−Abがリウマチ診断における日常検査
に非常に有用であることが示された。
[Table] The positive rate of the RP-Ab method in patients with rheumatoid arthritis was 76.7% (23.3% false negative), while the positive rate of the RA test was 60.0% (40.0% false negative), indicating that sensitivity is RP compared to RA test
-Ab method was clearly higher. Also, healthy people,
In patients with renal failure, liver disease, and cancer, the RP-Ab method had no false positives, whereas the RA test had false positives of 6.7% to 33.3%, depending on the disease. , R.A.
The RP-Ab method was clearly more specific than the test. From the above results, compared to the conventional method of measuring rheumatoid factor, RP
The rheumatism diagnosis method using the -Ab method is clearly superior, and it has been shown that RP-Ab is very useful for routine tests in rheumatism diagnosis.

【図面の簡単な説明】[Brief explanation of drawings]

第1図は精製RPの2次元電気泳動像、第2図
は慢性関節リウマチ患者血漿の2次元電気泳動
像、第3図は健常人血漿の2次元電気泳動像、第
4図はRP−Abの沈降スポツトである。
Figure 1 is a two-dimensional electrophoretic image of purified RP, Figure 2 is a two-dimensional electrophoretic image of rheumatoid arthritis patient plasma, Figure 3 is a two-dimensional electrophoretic image of healthy human plasma, and Figure 4 is RP-Ab. It is a sedimentation spot.

Claims (1)

【特許請求の範囲】 1 SDSポリアクリルアミドゲル電気泳動で約
170000の分子量を示し、蛋白変性剤を用いない2
次元電気泳動における等電点が7.3〜7.8、移動度
(アルブミン最先端部の移動度を1.0として)が
0.40〜0.55の範囲にあり、アミノ酸組成が下記の
とおりである、リウマチ血漿中より取得されたリ
ウマチ特異蛋白質。 アミノ酸組成(単位はmole%) Lys 6.6, His 1.9, Arg 4.0, Asp
7.0,Thr 8.5, Ser10.0, Glu 10.4, Pro
7.9,Gly10.4, Ala 4.7, Cys/2 1.0,Val
7.5,Met 1.6, Ile 2.9, Leu 8.3, Tyr
4.5,Phe 2.9
[Claims] 1. Approx.
Shows a molecular weight of 170,000 and does not use protein denaturants2
The isoelectric point in dimensional electrophoresis is 7.3-7.8, and the mobility (assuming the mobility of the leading edge of albumin is 1.0)
A rheumatoid-specific protein obtained from rheumatoid plasma and having an amino acid composition in the range of 0.40 to 0.55 as shown below. Amino acid composition (unit: mole%) Lys 6.6, His 1.9, Arg 4.0, Asp
7.0, Thr 8.5, Ser10.0, Glu 10.4, Pro
7.9, Gly10.4, Ala 4.7, Cys/2 1.0, Val
7.5, Met 1.6, Ile 2.9, Leu 8.3, Tyr
4.5,Phe 2.9
JP58053922A 1983-03-31 1983-03-31 Rheumatic specific protein and antibody thereof Granted JPS59180363A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58053922A JPS59180363A (en) 1983-03-31 1983-03-31 Rheumatic specific protein and antibody thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58053922A JPS59180363A (en) 1983-03-31 1983-03-31 Rheumatic specific protein and antibody thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP24249090A Division JPH03218464A (en) 1990-09-14 1990-09-14 Antibody to rheumatism-specific protein

Publications (2)

Publication Number Publication Date
JPS59180363A JPS59180363A (en) 1984-10-13
JPH0526800B2 true JPH0526800B2 (en) 1993-04-19

Family

ID=12956206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58053922A Granted JPS59180363A (en) 1983-03-31 1983-03-31 Rheumatic specific protein and antibody thereof

Country Status (1)

Country Link
JP (1) JPS59180363A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175310B1 (en) * 1984-09-14 1990-12-12 ASAHI MEDICAL Co., Ltd. A substantially pure rheumatoid arthritis specific protein and an antibody against the same
JPS6216499A (en) * 1985-07-16 1987-01-24 Asahi Medical Co Ltd Antirheumatism-specific protein monoclonal antibody and cell strain

Also Published As

Publication number Publication date
JPS59180363A (en) 1984-10-13

Similar Documents

Publication Publication Date Title
Tomasi et al. The selective occurrence of γ 1 A globulins in certain body fluids
Kawai Clinical aspects of the plasma proteins
CA1183451A (en) Method for producing a csap tryptic peptide and anti- csap antibodies
James et al. Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus)
Lin et al. Three pregnancy-associated human plasma proteins: purification, monospecific antisera and immunological identification
JPS59225196A (en) Tissue protein and isolation
EP0313156B1 (en) Snrnp-a antigen and fragments thereof
Brandtzaeg HUMAN SECRETORY IMMUNOGLOBULINS: 4. Quantitation of Free Secretory Piece
Echetebu et al. Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase.
JPS62501563A (en) Proteins characteristic of rheumatoid arthritis
JPH0354679B2 (en)
Tschopp et al. Occurrence of an incomplete C8 molecule in homozygous C8 deficiency in man.
JPH0678788A (en) Method of testing bone fragility and osteoporosis for danger of fracture
Kitamura et al. Immunochemical analysis of the monoclonal paraprotein in scleromyxedema
Kaplan et al. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
CA2071530A1 (en) Diagnosis of glomerulonephritis
Green et al. Urinary loss of clotting factors due to hereditary membranous glomerulopathy
JPH0526800B2 (en)
JPH0541640B2 (en)
Glueck et al. A monoclonal immunoglobulin A (κ) factor VIII: C inhibitor associated with primary amyloidosis: Identification and characterization
Moroz et al. A hereditary immunoglobulin A abnormality: absence of light-heavy—chain assembly: Study of immunoglobulin synthesis in tonsillar cells
McLeod et al. 'Hypocryoglobulins': Enhanced Cryoprecipitation From Hypotonic Serum in Patients With Vasculitis
WO1986000924A1 (en) Process for preparing human proline hydroxylase
JP3165828B2 (en) Malignant tumor detection method and kit
Ayala et al. Immunochemical characterization of the abnormal paraprotein in a case of scleromyxoedema